Cabio Total Revenue vs Research Development Analysis

688089 Stock

18.28 0.19 1.05%

Cabio Biotech financial indicator trend analysis is way more than just evaluating Cabio Biotech Wuhan prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cabio Biotech Wuhan is a good investment. Please check the relationship between Cabio Biotech Total Revenue and its Research Development accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabio Biotech Wuhan. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Total Revenue vs Research Development

Total Revenue vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cabio Biotech Wuhan Total Revenue account and Research Development. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Cabio Biotech's Total Revenue and Research Development is 0.96. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Research Development in the same time period over historical financial statements of Cabio Biotech Wuhan, assuming nothing else is changed. The correlation between historical values of Cabio Biotech's Total Revenue and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Cabio Biotech Wuhan are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Total Revenue i.e., Cabio Biotech's Total Revenue and Research Development go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Revenue

Total revenue comprises all receipts Cabio Biotech Wuhan generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Research Development

Most indicators from Cabio Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cabio Biotech Wuhan current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabio Biotech Wuhan. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

The current year's Tax Provision is expected to grow to about 17.8 M, whereas Selling General Administrative is forecasted to decline to about 35.2 M.

	2022	2023	2024	2025 (projected)
Gross Profit	182.7M	188.2M	216.4M	169.2M
Total Revenue	433.4M	443.8M	510.4M	353.1M

Gross Profit Total Revenue

Cabio Biotech fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Intangible Assets	Other Current Liab	Common Stock Shares Outstanding	Net Invested Capital	Net Working Capital	Capital Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Other Assets	Other Stockholder Equity
Total Assets		0.59	1.0	0.98	0.81	0.73	0.75	0.71	0.96	-0.76	0.16	0.82	0.58	-0.57	0.89	0.29	0.5	0.89	1.0	0.84	0.89	-0.8	0.83	0.78	0.71	-0.89
Total Current Liabilities	0.59		0.54	0.54	0.84	0.07	0.69	0.23	0.63	-0.55	0.49	0.67	1.0	0.18	0.28	0.75	0.52	0.56	0.56	0.18	0.56	-0.83	0.65	0.79	0.3	-0.6
Total Stockholder Equity	1.0	0.54		0.98	0.78	0.76	0.73	0.72	0.96	-0.75	0.12	0.8	0.53	-0.61	0.91	0.24	0.48	0.88	1.0	0.86	0.88	-0.77	0.81	0.75	0.72	-0.89
Retained Earnings	0.98	0.54	0.98		0.79	0.69	0.76	0.79	0.95	-0.81	0.13	0.82	0.53	-0.65	0.86	0.27	0.46	0.88	0.98	0.8	0.88	-0.8	0.84	0.77	0.78	-0.91
Accounts Payable	0.81	0.84	0.78	0.79		0.38	0.91	0.45	0.83	-0.84	0.31	0.93	0.83	-0.26	0.58	0.58	0.47	0.75	0.8	0.5	0.76	-0.93	0.85	0.86	0.54	-0.83
Cash	0.73	0.07	0.76	0.69	0.38		0.25	0.57	0.59	-0.38	-0.48	0.37	0.06	-0.66	0.96	-0.41	0.59	0.42	0.75	0.98	0.42	-0.22	0.35	0.14	0.58	-0.61
Non Current Assets Total	0.75	0.69	0.73	0.76	0.91	0.25		0.5	0.8	-0.81	0.52	0.99	0.68	-0.25	0.48	0.63	0.11	0.84	0.76	0.42	0.86	-0.93	0.93	0.9	0.58	-0.8
Non Currrent Assets Other	0.71	0.23	0.72	0.79	0.45	0.57	0.5		0.6	-0.44	0.02	0.51	0.22	-0.53	0.66	-0.07	0.36	0.57	0.72	0.65	0.57	-0.55	0.63	0.44	0.98	-0.77
Net Receivables	0.96	0.63	0.96	0.95	0.83	0.59	0.8	0.6		-0.85	0.28	0.86	0.62	-0.54	0.79	0.44	0.36	0.94	0.96	0.72	0.94	-0.85	0.84	0.86	0.59	-0.8
Non Current Liabilities Total	-0.76	-0.55	-0.75	-0.81	-0.84	-0.38	-0.81	-0.44	-0.85		-0.16	-0.85	-0.53	0.6	-0.58	-0.47	-0.25	-0.76	-0.75	-0.5	-0.77	0.8	-0.77	-0.78	-0.46	0.69
Inventory	0.16	0.49	0.12	0.13	0.31	-0.48	0.52	0.02	0.28	-0.16		0.43	0.5	0.38	-0.26	0.85	-0.41	0.53	0.14	-0.31	0.52	-0.54	0.51	0.67	0.0	-0.16
Other Current Assets	0.82	0.67	0.8	0.82	0.93	0.37	0.99	0.51	0.86	-0.85	0.43		0.66	-0.34	0.58	0.57	0.18	0.87	0.83	0.53	0.89	-0.92	0.93	0.89	0.58	-0.83
Total Liab	0.58	1.0	0.53	0.53	0.83	0.06	0.68	0.22	0.62	-0.53	0.5	0.66		0.2	0.27	0.75	0.52	0.55	0.55	0.17	0.55	-0.83	0.65	0.79	0.29	-0.6
Short Long Term Debt	-0.57	0.18	-0.61	-0.65	-0.26	-0.66	-0.25	-0.53	-0.54	0.6	0.38	-0.34	0.2		-0.67	0.24	-0.17	-0.45	-0.57	-0.67	-0.45	0.21	-0.34	-0.21	-0.46	0.44
Total Current Assets	0.89	0.28	0.91	0.86	0.58	0.96	0.48	0.66	0.79	-0.58	-0.26	0.58	0.27	-0.67		-0.16	0.59	0.64	0.9	0.99	0.65	-0.47	0.57	0.41	0.67	-0.77
Intangible Assets	0.29	0.75	0.24	0.27	0.58	-0.41	0.63	-0.07	0.44	-0.47	0.85	0.57	0.75	0.24	-0.16		-0.12	0.56	0.25	-0.26	0.56	-0.7	0.57	0.81	-0.05	-0.28
Other Current Liab	0.5	0.52	0.48	0.46	0.47	0.59	0.11	0.36	0.36	-0.25	-0.41	0.18	0.52	-0.17	0.59	-0.12		0.1	0.48	0.53	0.09	-0.3	0.19	0.14	0.42	-0.51
Common Stock Shares Outstanding	0.89	0.56	0.88	0.88	0.75	0.42	0.84	0.57	0.94	-0.76	0.53	0.87	0.55	-0.45	0.64	0.56	0.1		0.89	0.58	1.0	-0.84	0.9	0.91	0.55	-0.77
Net Invested Capital	1.0	0.56	1.0	0.98	0.8	0.75	0.76	0.72	0.96	-0.75	0.14	0.83	0.55	-0.57	0.9	0.25	0.48	0.89		0.86	0.89	-0.78	0.83	0.76	0.72	-0.9
Net Working Capital	0.84	0.18	0.86	0.8	0.5	0.98	0.42	0.65	0.72	-0.5	-0.31	0.53	0.17	-0.67	0.99	-0.26	0.53	0.58	0.86		0.59	-0.38	0.51	0.32	0.66	-0.72
Capital Stock	0.89	0.56	0.88	0.88	0.76	0.42	0.86	0.57	0.94	-0.77	0.52	0.89	0.55	-0.45	0.65	0.56	0.09	1.0	0.89	0.59		-0.84	0.91	0.91	0.55	-0.78
Other Liab	-0.8	-0.83	-0.77	-0.8	-0.93	-0.22	-0.93	-0.55	-0.85	0.8	-0.54	-0.92	-0.83	0.21	-0.47	-0.7	-0.3	-0.84	-0.78	-0.38	-0.84		-0.89	-0.95	-0.6	0.79
Net Tangible Assets	0.83	0.65	0.81	0.84	0.85	0.35	0.93	0.63	0.84	-0.77	0.51	0.93	0.65	-0.34	0.57	0.57	0.19	0.9	0.83	0.51	0.91	-0.89		0.88	0.67	-0.83
Property Plant And Equipment Net	0.78	0.79	0.75	0.77	0.86	0.14	0.9	0.44	0.86	-0.78	0.67	0.89	0.79	-0.21	0.41	0.81	0.14	0.91	0.76	0.32	0.91	-0.95	0.88		0.45	-0.72
Other Assets	0.71	0.3	0.72	0.78	0.54	0.58	0.58	0.98	0.59	-0.46	0.0	0.58	0.29	-0.46	0.67	-0.05	0.42	0.55	0.72	0.66	0.55	-0.6	0.67	0.45		-0.82
Other Stockholder Equity	-0.89	-0.6	-0.89	-0.91	-0.83	-0.61	-0.8	-0.77	-0.8	0.69	-0.16	-0.83	-0.6	0.44	-0.77	-0.28	-0.51	-0.77	-0.9	-0.72	-0.78	0.79	-0.83	-0.72	-0.82

Click cells to compare fundamentals

Cabio Biotech Account Relationship Matchups

Cabio Biotech fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.4B	1.4B	1.6B	1.6B	1.9B	1.2B
Total Current Liabilities	52.3M	60.0M	180.4M	112.4M	129.3M	82.2M
Total Stockholder Equity	1.3B	1.4B	1.4B	1.5B	1.7B	1.1B
Retained Earnings	327.9M	416.9M	375.4M	421.3M	484.5M	291.8M
Accounts Payable	24.5M	31.4M	107.3M	70.9M	81.5M	85.6M
Cash	847.3M	664.5M	494.3M	239.7M	275.6M	458.3M
Non Current Assets Total	259.7M	453.6M	703.5M	902.7M	1.0B	1.1B
Non Currrent Assets Other	23.6M	74.9M	17.5M	28.2M	32.4M	22.2M
Net Receivables	128.5M	151.1M	189.0M	214.8M	247.0M	149.9M
Non Current Liabilities Total	7.0M	6.7M	5.3M	5.2M	4.7M	5.1M
Inventory	65.5M	74.9M	81.5M	112.6M	129.5M	87.9M
Other Current Assets	20.9M	24.7M	41.8M	51.3M	59.0M	61.9M
Total Liab	59.3M	66.7M	185.8M	117.6M	135.2M	89.2M
Total Current Assets	1.1B	994.9M	907.4M	708.8M	815.1M	790.9M
Intangible Assets	14.5M	13.2M	36.3M	41.1M	47.2M	26.8M
Other Current Liab	10.3M	9.6M	22.6M	270.6K	311.2K	295.6K
Net Invested Capital	1.3B	1.4B	1.5B	1.5B	1.7B	1.2B
Net Working Capital	1.1B	934.9M	726.9M	596.4M	685.8M	779.8M
Property Plant And Equipment Net	149.5M	241.9M	486.0M	643.3M	739.8M	370.6M
Property Plant And Equipment Gross	406.0M	513.7M	486.0M	970.2M	1.1B	610.7M

Currently Active Assets on Macroaxis

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin
ADA	Cardano
XRP	XRP

Other Information on Investing in Cabio Stock

Balance Sheet is a snapshot of the financial position of Cabio Biotech Wuhan at a specified time, usually calculated after every quarter, six months, or one year. Cabio Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cabio Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cabio currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cabio Total Revenue vs Research Development Analysis

Total Revenue vs Research Development

Total Revenue vs Research Development Correlation Analysis

Correlation Coefficient

Total Revenue

Research Development

Cabio Biotech fundamental ratios Correlations

Cabio Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cabio Biotech fundamental ratios Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Cabio Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Stock	+ 1.0	Common Stock Shares Outstanding
Other Current Assets	+ 0.99	Non Current Assets Total

Property Plant And Equipment Net	- 0.95	Other Liab
Other Liab	- 0.93	Non Current Assets Total
Other Liab	- 0.93	Accounts Payable
Other Liab	- 0.92	Other Current Assets
Other Stockholder Equity	- 0.91	Retained Earnings
Other Stockholder Equity	- 0.9	Net Invested Capital